Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Common Equity: 2019-2024

Historic Common Equity for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $1.4 billion.

  • Avidity Biosciences' Common Equity rose 25.47% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 25.47%. This contributed to the annual value of $1.4 billion for FY2024, which is 184.56% up from last year.
  • According to the latest figures from FY2024, Avidity Biosciences' Common Equity is $1.4 billion, which was up 184.56% from $500.8 million recorded in FY2023.
  • In the past 5 years, Avidity Biosciences' Common Equity ranged from a high of $1.4 billion in FY2024 and a low of $306.2 million during FY2020.
  • Its 3-year average for Common Equity is $834.6 million, with a median of $578.1 million in 2022.
  • As far as peak fluctuations go, Avidity Biosciences' Common Equity skyrocketed by 568.54% in 2020, and later fell by 13.37% in 2023.
  • Avidity Biosciences' Common Equity (Yearly) stood at $306.2 million in 2020, then increased by 24.56% to $381.4 million in 2021, then skyrocketed by 51.55% to $578.1 million in 2022, then fell by 13.37% to $500.8 million in 2023, then soared by 184.56% to $1.4 billion in 2024.